Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release

BACKGROUND: Therapeutic options currently available for metastatic castration-resistant prostate cancer (mCRPC) do not extend median overall survival >6 months. Therefore, the development of novel and effective therapies for mCRPC represents an urgent medical need. T cell engagers (TCEs) have eme...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Immunother Cancer
Autors principals: Dang, Kevin, Castello, Giulia, Clarke, Starlynn C, Li, Yuping, Balasubramani, Aarti, Boudreau, Andrew, Davison, Laura, Harris, Katherine E, Pham, Duy, Sankaran, Preethi, Ugamraj, Harshad S, Deng, Rong, Kwek, Serena, Starzinski, Alec, Iyer, Suhasini, van Schooten, Wim, Schellenberger, Ute, Sun, Wenchao, Trinklein, Nathan D, Buelow, Roland, Buelow, Ben, Fong, Lawrence, Dalvi, Pranjali
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2021
Matèries:
Clinical/Translational Cancer Immunotherapy
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8183203/
https://ncbi.nlm.nih.gov/pubmed/34088740
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2021-002488
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars